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Chromatin-mediated processes influence the devel-
opment and progression of breast cancer. Using mu-
rinemammary carcinoma-derived tumorspheres as a
functional readout for an aggressive breast cancer
phenotype, we performed a loss-of-function screen
targeting 60 epigenetic regulators. We identified the
Polycomb protein Cbx8 as a key regulator of mam-
mary carcinomaboth in vitro and in vivo. Accordingly,
Cbx8 is overexpressed in human breast cancer
and correlates with poor survival. Our genomic
analyses revealed that Cbx8 positively regulates
Notch signaling by maintaining H3K4me3 levels on
Notch-network gene promoters. Ectopic expression
of Notch1 partially rescues tumorsphere formation in
Cbx8-depleted cells. We find that Cbx8 associates
with non-PRC1 complexes containing the H3K4
methyltransferasecomplexcomponentWDR5,which
together regulate Notch gene expression. Thus, our
study implicates a key non-canonical role for Cbx8
in promoting breast tumorigenesis.
INTRODUCTION
Chromatin modifiers have been increasingly reported as regula-
tors of tumorigenicity (Shen and Laird, 2013; Vardabasso et al.,
2014). Recent studies also suggest that tumor heterogeneity and
tumor cell plasticity may be under epigenetic control (Easwaran
et al., 2014). For example, in the context of breast cancer, EZH2
promotes the expansion of breast-tumor-initiating cells and
KDM5B/JARID1B acts as an oncogene in luminal breast tumor
cells (Chang et al., 2011; Yamamoto et al., 2014). Such epigenetic
regulators, which mediate reversible changes at the chromatin
level, may be targetable therapeutically (Campbell and Tummino,
2014). However, the epigenetic mechanisms at play in the devel-
opment of breast cancer remain poorly understood.472 Cell Reports 16, 472–486, July 12, 2016 ª 2016 The Author(s).
This is an open access article under the CC BY-NC-ND license (http://Polycomb Repressive Complexes (PRC1 and PRC2) regulate
chromatin states during development and have been linked to
cancer (Aloia et al., 2013; Mills, 2010; Whitcomb et al., 2007).
PRC2 performs its repressive function by catalyzing H3K27
methylation and PRC1 mediates gene silencing through mono-
ubiquitylation of H2AK119 in an H3K27me3-dependent or -inde-
pendent manner (Tavares et al., 2012). Canonical PRC1 is
comprised of four subunits, including a Ring E3 ubiquitin ligase,
Polyhomeotic, Posterior sex combs, and Polycomb (which binds
H3K27me3 through its chromodomain) (Whitcomb et al., 2007).
However, variant PRC1 complexes have been identified in mam-
mals, which contain distinct Polycomb Group family members
and/or alternate proteins, such as chromatin modifying enzymes
and transcription factors (Gao et al., 2012).
Mammalian genomes encode five Polycomb orthologs known
as theChromobox (Cbx)members Cbx2, 4, 6, 7, and 8 (Bernstein
et al., 2006;Whitcomb et al., 2007).We and others demonstrated
that Cbx7 is the predominant Polycomb protein expressed in
mouse embryonic stem cells (ESCs), where it maintains self-
renewal and pluripotency, while Cbx8 promotes ESC differentia-
tion by repressing pluripotency genes (Morey et al., 2012;
O’Loghlen et al., 2012). Both CBX7 and CBX8 have been linked
to cancer through their ability to bypass senescence by repres-
sing the Ink4a/Arf locus and cooperate with oncogenes to initiate
hematopoietic malignancies (Dietrich et al., 2007; Gil et al., 2004;
Scott et al., 2007; Tan et al., 2011).CBX8 is altered in a number of
cancers, including glioblastoma and esophageal squamous cell
carcinoma (Li et al., 2013; Zhang et al., 2015); however, a role for
CBX8 in breast cancer remains unclear.
The Notch signaling pathway regulates normal mammary
gland development and plays a key role in mammary progenitor
cell maintenance (Reedijk, 2012). In breast cancer, upregulation
of Notch receptors and ligands has been shown to correlate with
high-grade tumors and poor patient prognosis and to confer
drug resistance, particularly in the triple-negative subtype that
lacks targeted therapies (Magnani et al., 2013; Reedijk et al.,
2005). In addition, Notch signaling is required for tumor-initiating
properties (D’Angelo et al., 2015; Farnie et al., 2007). Genomic
alternations of Notch gene loci appear rarely in solid tumors,creativecommons.org/licenses/by-nc-nd/4.0/).
and Notch hyperactivation may be driven by epigenetic events
(Reedijk, 2012). Thus, targeting theNotch pathway through chro-
matin regulation may be an important avenue to treat breast
cancer.
Using tumorspheres (TS) to enrich for highly tumorigenic cell
populations, we have conducted an RNAi screen to uncover
epigenetic factors essential for breast tumorigenicity and identi-
fied the Polycomb ortholog Cbx8. Cbx8 promotes TS formation
andmammary tumorigenesis in vivo and is upregulated in human
breast tumors.We further demonstrate that Cbx8 sustains Notch
gene expression by maintaining the transcriptionally active his-
tone modification H3K4me3 on Notch gene promoters, as well
as other Notch-network genes. We find that Cbx8 interacts
with Wdr5, a core component of H3K4 methyltransferase com-
plexes, and that loss of Wdr5 phenocopies Cbx8 loss. Collec-
tively, the functional and biochemical studies presented here
demonstrate a non-canonical role for Cbx8 in breast cancer
through activation of genes involved in Notch signaling.
RESULTS
Mammary Tumorspheres Enrich for Tumorigenic Cells
and Provide a Robust Screening System
In order to identify chromatin regulators required for breast
tumorigenicity we used TS culture, which enriches for cells
with tumor-initiating properties (Dontu et al., 2003; Kurpios
et al., 2013). We utilized the mammary carcinoma mouse
model MMTV-Myc, which generates heterogeneous and highly
aggressive tumors (Andrechek et al., 2009; Bosch et al.,
2012), and reproducibly generates TS (Figure 1A). By culturing
cells from MMTV-myc tumors in bulk (adherent) or TS condi-
tions, we detected an increase of CD49f+/CD24 population,
suggesting enrichment of cells associated with basal subtype
characteristics (Figure S1A). Further, RNA sequencing (RNA-
seq) analysis of bulk versus TS cultures revealed a distinct
high-grade tumor and basal subtype gene expression program
in TS (Figures S1B and S1C; Table S1). Importantly, we demon-
strated that TS cells are more tumorigenic than bulk cells
through in vivo mammary fat pad injections at limiting dilutions
(Figure 1B). This suggests that by culturing mammary tumor
cells as TS, we enrich for a cell population with higher
tumorigenic potential. Because we observed that propagating
MMTV-Myc TS was quite robust in comparison to TS from other
tumor models (e.g., MMTV-neu model; data not shown), we
used this model for pooled RNAi screens, which requires selec-
tion over time to allow effective competition of short hairpin
RNAs (shRNAs).
TS Loss-of-Function Screen Identifies a Dependency
on Cbx8
We developed a functional screen in TS culture using lentiviral
transduction of a pool of shRNAs, followed by high-throughput
sequencing. We created and utilized an shRNA library targeting
60 epigenetic factors (Figure 1C; Table S2), averaging 7 shRNAs
per gene (total of 452 shRNAs). Cells were dissociated from two
transplantedMMTV-Myc tumors and cultured as TS, which were
maintained in suspension during the entire screening process to
maintain tumorigenic properties. Two independent TS culturesfrom each tumor were cultured to serve as technical replicates.
In addition, we performed the screen in bulk cells as a control
for shRNAs that affect proliferation or survival. Bulk and TS cells
were collected at three time points (baseline, day 12, and
day 20), genomic DNA was extracted, and the shRNA pool
was amplified by PCR and subjected to high-throughput
sequencing analysis (Figure 1D).
Over 90% of shRNAs were present (>500 reads) at baseline,
which were used as a reference for comparison with later time
points. In addition, the average reads between the two tumors
showed high correlation as they clustered together at each
time point using unsupervised hierarchical clustering (Fig-
ure S1D). The screen produced 18% of shRNAs with significant
TS-specific depletions (Figure S1E; Table S3). The candidates
were then further filtered by the following criteria: (1) genes
with > 2 shRNAs present in the library at baseline and (2) >
33% shRNAs significantly changed. The resulting hits were
ranked by their percent of genomic alterations from The Cancer
Genome Atlas (TCGA) datasets for breast cancer (Figure S1F).
The Polycomb family member Cbx8 was among the top compel-
ling candidates, showing significant TS-specific shRNA deple-
tion at both early and late time points (Figure 1E) and is amplified
and/or upregulated transcriptionally in 10% of breast tumors
(Figure 1F).
Cbx8 Promotes a Tumorigenic Phenotype in Breast
Cancer Cells
We validated Cbx8 as a candidate using two individual shRNAs
that were contained within the shRNA pool (Figures 2A and 2B).
In addition, we knocked down human CBX8 in four distinct
human breast cancer cell lines, including MCF7 (luminal), T47D
(luminal), MDA-MB-157 (basal), and MDA-MB-231-Luc (basal)
(Figure 2C). We observed that knockdown of Cbx8 in both
mouse and human cells significantly decreased TS formation
(Figures 2B and 2C). These results not only validate our TS
screening approach but also extend the mouse mammary carci-
noma findings to human breast cancer cells.
Next, we performed functional assays to assess the effect of
Cbx8 depletion in both mouse and human cell lines. We cultured
cells in extracellular matrix (Matrigel) to examine their invasive-
ness versus differentiation capacity in 3D culture (Debnath
et al., 2003). For example, non-tumorigenic MCF10A cells form
highly organized acinar structures, whereas MDA-MB-231-Luc
cells formed disorganized structures that invade the extracellular
matrix (Figure S2A). By knocking down Cbx8 in MMTV-Myc and
MDA-MB-231-Luc cells, we observed a significant reduction
of invasive colonies, with some displaying cavitation, which is
typical of acini morphogenesis (Figures 2D, 2E, S2B, and S2C).
We also performed clonogenicity assays to examine the ability
of cells to initiate colonies at low density. Using control (shLuc
or shScr) and Cbx8 knockdown in MMTV-Myc and MDA-MB-
231-Luc cells, we observed a requirement of Cbx8 for colony
initiation in vitro (Figures 2F, 2G, S2D, and S2E). While Cbx8
has been reported to repress Ink4a/Arf, we did not observe
senescence-like growth arrest (Figures S2F and S2G) or the in-
duction of senescence markers upon Cbx8 knockdown (Figures
S2H and S2I). In addition, we did not observe clear perturbation
of epithelial-to-mesenchymal (EMT) markers and luminal andCell Reports 16, 472–486, July 12, 2016 473
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Figure 1. Functional RNAi Screen Targeting Epigenetic Factors in TS
(A) Bright-field images of MMTV-Myc bulk and TS cells. Scale bar, 100 mm.
(B) In vivo tumor growth (mammary fat pad) of bulk and TSMMTV-Myc cells at 13 102, 13 103, and 13 105 cells per injection. Mean ± SEM (n = 4 injections per
group). *p < 0.05, **p < 0.001.
(C) Pie chart depicting the composition of the chromatin-focused shRNA library used in the TS screen. Numbers indicate genes per category (total = 60).
(D) Mammary TS RNAi screening strategy.
(E) Scatter plots of normalized shRNA reads of bulk and TS screens at the indicated time points. Significantly depleted Cbx8 shRNAs (p < 0.1) are highlighted in
blue; red dotted lines represent 2-fold change.
(F) CBX8 alterations in breast cancer patients (n = 463) from TCGA datasets (Cancer Genome Atlas, 2012).
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Figure 2. Cbx8 Sustains Tumorigenic Phenotypes of Mammary Carcinoma Cells
(A) Immunoblot of Cbx8 knockdown using two individual shRNAs in MMTV-Myc cells. Histone H3 used as loading control; numbers indicate relative intensity of
bands normalized to H3.
(B) RNAi screen validation of TS formation upon Cbx8 knockdown (left). Mean ± SEM (n = 10). Representative images of individual 96 wells are shown (right).
(C) TS formation in human breast cancer cell lines uponCBX8 knockdown (top). Mean ±SEM (n = 10). Immunoblot of control and CBX8 knockdown cells (bottom).
Histone H3 used as loading control.
(D) Bright-field and confocal images of control and Cbx8 knockdown MMTV-Myc cells plated on Matrigel. Scale bars, 50 mm.
(E) Quantification of invasive colonies in (D). Mean ± SEM (n = 3).
(F) Clonogenic ability of control and Cbx8 knockdown MMTV-Myc cells.
(G) Quantification of clonogenicity in (F). Mean ± SEM (n = 3).
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Figure 3. Cbx8 Promotes Mammary Tumorigenesis In Vivo
(A) Tumor growth upon mammary fat pad injection of 1 3 103 control and Cbx8 knockdown MMTV-Myc cells; tumor size and tumor weight (day 24, end point)
shown. Mean ± SEM (n = 13 for shScr, n = 15 for shCbx8). **p < 0.001.
(B) Real-time qPCR analysis of CBX8 mRNA expression in two normal and six breast cancer cell lines, including luminal (Lu), basal (Ba), and claudin-low (Cl)
molecular subtypes. GAPDH was used for normalization. Mean ± SEM (n = 3). *p < 0.05, **p < 0.01, ***p < 0.001 (all tested to human mammary epithelial cell
[HMEC]).
(C) Boxplot of CBX8 mRNA expression in paired normal tissue and primary tumor (n = 94); RNA-seq from TCGA. Square dots, sample mean; bold lines, median;
boxes, 25–75 percentiles; whiskers, 1.5 3 interquartile range (IQR); notches, 95% CI. Outliers are not shown.
(D) Kaplan-Meier graph representing the probability of cumulative overall survival in breast cancer patients (n = 597). Tumors were grouped by top 25% (CBX8
high) and lower 75%CBX8 (CBX8 low) expression. Log rank test p value is shown. Patient data from (C) and (D) are extracted from TCGA (Cancer Genome Atlas,
2012).basal markers upon Cbx8 loss (Figures S2H and S2I). This sug-
gests that Cbx8 functions to regulate alternative gene expres-
sion programs in breast cancer.
Cbx8 Is Required for Tumor Growth In Vivo and
Correlates with Poor Survival
Wenext investigated the role of Cbx8 inmediating tumorigenesis
in vivo. To do so, only 1,000 control and Cbx8 knockdown
MMTV-Myc cells were injected into mouse mammary fat pads
andmonitored over a period of 24 days. Cbx8 knockdown signif-
icantly reduced tumor growth as measured by both tumor size
and weight (Figure 3A), suggesting that Cbx8 is indeed required
for tumor growth in vivo.
We next extended our studies to human breast cancer. Inter-
estingly, breast cancer is one of the most common cancer types
with CBX8 genomic alterations (Figure S3A) (Gao et al., 2013).
First, we examined the expression levels of CBX8 by real-time
qPCR in a panel of breast cancer cell lines that includes non-tu-
morigenic cells (human mammary epithelial cells and MCF10A)
as well as luminal and basal subtypes. All of the tumorigenic cells476 Cell Reports 16, 472–486, July 12, 2016displayed a significant increase of CBX8 levels regardless of mo-
lecular subtype (Figure 3B). Next, we examined the TCGA data-
sets to identify correlations between CBX8 expression and the
occurrence of breast cancer. CBX8 copy-number amplification
correlates with high mRNA levels, suggesting that the increased
expression can be partially explained by copy-number gain (Fig-
ure S3B). Moreover, CBX8 mRNA levels are higher in primary
tumors versus normal tissues (Figure 3C). Similar to breast can-
cer cell lines (Figure 3B), increased levels of CBX8 in patient
samples does not correlate with a specific subtype (Figure S3C),
suggesting that CBX8 is a general regulator of breast tumorigen-
esis. Finally, from TCGA datasets and two other studies (Cancer
Genome Atlas, 2012; Hu et al., 2006b; Loi et al., 2008), high
CBX8 expression predicts poor prognosis (Figures 3D, S3D,
and S3E).
Cbx8 Maintains a Stem Cell-like Gene Expression
Program and Notch Signaling
To further understand the role of Cbx8 in promoting tumorigen-
esis, we conducted transcriptional profiling by RNA-seq. By
A B
C D E
F G
H I
Figure 4. Cbx8 Regulates Stem Cell-like Gene Expression Including Notch Signaling
(A) Representation of genes up- and downregulated (>2 fold) after Cbx8 knockdown in MMTV-Myc cells, as analyzed by RNA-seq.
(B) Gene set enrichment analysis (GSEA) of gene expression changes upon Cbx8 knockdown in MMTV-Myc cells using published stem cell gene signatures.
(C) Representation of Notch-network gene expression changes (RNA-seq) upon Cbx8 knockdown in MMTV-Myc cells.
(legend continued on next page)
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comparing mRNA expression between control and Cbx8 knock-
downMMTV-Myc cells, we found 188 genes upregulated (‘‘Cbx8
KD up’’) and 259 genes downregulated (‘‘Cbx8 KD down’’) with
greater than 2-fold change (Figure 4A; Table S1). Gene Ontology
(GO) analysis revealed that Cbx8 KD up genes are involved
in stimulus response and nucleosome assembly, whereas
Cbx8 KD down genes are involved in developmental processes
(Figure S4A; Table S1). Using gene set enrichment analysis
(GSEA), we found a significant anti-correlation of Cbx8 knock-
down with fetal mammary stem cell (fMaSC) and ESC gene sig-
natures (Figure 4B) (Ben-Porath et al., 2008; Spike et al., 2012;
Wong et al., 2008). Collectively, these data indicate that Cbx8
maintains a stem cell-like gene expression program.
We next performed network analysis using MetaCore soft-
ware. In addition to several known oncogenic factors that are
altered, such as Wnt signaling components (Figure S4B), we
found the Notch signaling network to be most enriched upon
Cbx8 KD down (Table S4). Specifically, we observed that the
Notch1 receptor and its ligands Dll4 and Jag2 were downregu-
lated (>2-fold) in Cbx8 KD MMTV-Myc cells (Figure 4C). This
was confirmed by immunoblotting and real-time qPCR with
two individual shRNAs (Figure 4D). To determine whether this
translates into a diminution of Notch signaling, we utilized a
Notch reporter in MMTV-Myc TS. Indeed, Cbx8 loss resulted in
significant decrease of Notch activity and one shRNA (Cbx8-
sh69) produced a similar level of reduction as treatment with a
gamma secretase inhibitor (GSI) (Figure 4E).
We reasoned that if Cbx8 regulates Notch signaling, then
ectopic Notch1 expression should rescue the TS defect caused
byCbx8 loss. To test this, we knocked downCbx8 inMMTV-Myc
cells followed by ectopic expression of N1IC (Notch1 intracel-
lular domain) and tested the ability of the cells to form TS. Knock-
down efficiency of Cbx8 and Notch expression was validated by
real-time qPCR and immunoblotting (Figures S4C and S4D). As
expected, we observed decreased TS formation upon Cbx8
depletion. However, when N1IC was expressed in Cbx8 knock-
down cells, TS formation was partially restored (Figure 4F).
Together, these data indicate that Notch signaling is an impor-
tant downstream effector of Cbx8-mediated tumorigenesis.
To determine if the relation between Cbx8 and Notch holds
true in human breast cancer, we associated the expression of
NOTCH-network genes to the levels of CBX8 using RNA-seq
data from a panel of 82 human breast cell lines (Marcotte
et al., 2016) and validated by real-time qPCR using 9 of these
cell lines. We found that CBX8 positively correlates with several(D) Top: immunoblotting of Notch1 NTM (cleaved intracellular and transmembrane
control; numbers indicate relative intensity of bands normalized to H3. Bottom: rea
for normalization. Mean ± SEM (n = 3). *p < 0.05 compared to shScr.
(E) Notch-mCherry reporter activity in control and Cbx8 knockdown MMTV-My
fluorescence-activated cell sorting (FACS) (top); 2 mM of GSI; PF-384014 was us
(F) TS formation upon ectopic Notch expression in control and Cbx8 knockdown
(G) Heatmap showing the Spearman correlation of mRNA expression between C
(Marcotte et al., 2016) and real-time qPCR from 9 humanmammary cell lines (botto
are marked with black boxes.
(H) Real-time qPCR of Notch gene expression in bulk, day 8, and day 24 TS of MD
*p < 0.05 compared to bulk.
(I) Real-time qPCR of Notch gene expression in control and CBX8 knockdown MD
*p < 0.05 compared to shScr.
478 Cell Reports 16, 472–486, July 12, 2016NOTCH receptors, ligands, and target genes (Figure 4G). Here,
CBX8 most significantly correlated with NOTCH3 of the four
NOTCH receptors. Further, we observed a significant upregula-
tion of NOTCH3 receptor, as well as JAG1 and JAG2 ligand,
upon TS formation of MDA-MB-231-Luc cells compared to
bulk cells (Figure 4H). In accordance, knockdown of CBX8
in MDA-MB-231-Luc cells significantly decreased NOTCH3,
JAG1, and JAG2 expression (Figure 4I). Furthermore, CBX8
knockdown in three additional human breast cancer cell lines
showed that JAG2 is consistently downregulated upon CBX8
loss, while NOTCH3 decrease occurred more modestly (Fig-
ure S4E). Collectively, our data suggest that Cbx8 positively
regulates Notch-network genes in both human and mouse
breast cancer cells, with differential Notch receptor-ligand
regulation.
Cbx8 Is Required for Notch Expression In Vivo
We next examined the levels of Notch-network genes in trans-
planted tumors derived from control and Cbx8 knockdown
MMTV-myc cells. Cbx8 knockdown tumors showed reduction
of Notch1 and Dll4 protein levels (Figure 5A). Moreover, we
found a decrease in expression of Notch1, Dll4, and Jag2 genes
that were identified by RNA-seq analysis (Figure 4C), among
others (Figure 5B). Immunostaining of these tumors (see Fig-
ure 3A) showed a significant reduction of Notch1 signal in
Cbx8 knockdown tumors as compared to controls (Figure 5C).
These data suggest that Cbx8 regulates Notch gene expression
in vivo.
We sought to extend our observations to the epithelial cells
of the normal mammary gland. Notch has been reported to
repress the mammary stem cell state, while promoting differen-
tiation of the luminal lineage in mice (Bouras et al., 2008). Inter-
estingly, Cbx8 and Notch receptor-ligand expression positively
correlates in mammary epithelial cells. In fact, by correlating the
levels of Cbx8 and the Notch-network genes from isolated
luminal and basal populations, together with organoid cultures
that enrich for mammary epithelial stem cells (MaSCs), we
identified a strong correlation between Notch receptors and li-
gands and Cbx8 (Figures 5D and S5A). For example, organoid
cultures of MaSCs, which are low for Notch2 expression, are
also low for Cbx8 (Figure 5E). Conversely, basal and luminal
populations have higher levels of both (Figure 5E). Moreover,
knockdown and overexpression of Cbx8 in mammary organoid
cultures leads to decreased and increased levels of Notch2,
respectively (Figures S5B and S5C). Thus, we find that Notchdomain) and Dll4 in MMTV-Myc whole-cell lysate. Histone H3 used as loading
l-time qPCR of control and Cbx8 knockdownMMTV-Myc cells.Rpl7was used
c TS cells (bottom). Notch-mCherry positive population was determined by
ed as positive control for Notch inhibition. Mean ± SEM (n = 3).
MMTV-Myc cells (n = 20). ns, not significant.
BX8 and NOTCH genes from RNA-seq in 82 human mammary cell lines (top)
m; 8 fromFigure 3B, andMDA-MB-231 cells). Significant correlations (p < 0.05)
A-MB-231-Luc cells. GAPDHwas used for normalization. Mean ± SEM (n = 3).
A-MB-231-Luc cells.GAPDHwas used for normalization. Mean ± SEM (n = 3).
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Figure 5. Cbx8 Promotes Notch Expression in Mammary Tumors and Mammary Epithelial Cells
(A) Immunoblotting of Cbx8, Notch1 NTM, and Dll4 in whole-cell lysate of MMTV-Myc tumors (n = 3 individual tumors). B-actin was used as loading control;
numbers indicate relative intensity of bands normalized to b-actin.
(B) Real-time qPCR of Notch gene expression in control and Cbx8 knockdown MMTV-Myc tumors (see Figure 3). Individual data points and means are shown
(n = 3 individual tumors). Rpl7 was used for normalization.
(C) Notch1 immunostaining of control and Cbx8 knockdown MMTV-Myc tumors. Representative images were taken (203) with nuclei insets (403) from two
individual tumors. Scale bar, 100 mm.
(D) Top: FACS analysis of mouse mammary epithelial cells for luminal and basal populations (left). Bright-field image showing mammary organoids (right). Scale
bar, 200 mm. Bottom: heatmap representing the Spearman correlation of mRNA expression between Cbx8 and Notch genes in mouse mammary gland and
organoid culture (n = 4 for each luminal, basal, and organoid; total n = 12). Significant correlations (p < 0.05) are marked with black boxes.
(E) Scatter plot representing the expression correlation between Cbx8 and Notch2 from (D).signaling is also regulated by Cbx8 in normal mammary epithe-
lial cells.
Cbx8 Maintains H3K4me3 at Notch-Network Gene Loci
To gain insight into the mechanism by which Cbx8 regulates
Notch-network gene expression, we performed chromatin immu-
noprecipitation coupled to high-throughput sequencing (ChIP-seq) for histone modifications associated with gene expression
in control and Cbx8 knockdown MMTV-Myc cells. We examined
H3K27me3, the repressive modification directly bound by PRC1
complexes, as well as H3K27ac and H3K4me3, which mark
actively transcribed genes.
Strikingly, Cbx8 loss resulted in a global decrease of
H3K4me3 and H3K27ac, whereas H3K27me3 did not showCell Reports 16, 472–486, July 12, 2016 479
global changes (Figures 6A and S6A). Using SICER-df, which
identifies regions with significantly changed ChIP signals be-
tween samples, we found regions with significant changes (false
discovery rate [FDR] < 1 3 108 and fold change > 1.8) upon
Cbx8 knockdown. By mapping these significantly altered re-
gions to genes, we found H3K4me3 changes to be the most
evident with over 600 genes showing reduced H3K4me3 level
near their transcription start site (TSS) (Figure S6B; Table S5).
By overlapping these genes with Cbx8 KD down genes, we
found that Notch1, Jag2, and Dll4 displayed both decreased
mRNA expression and significant loss of H3K4me3 at their
TSS (Figure 6B). By examining the profile of these loci, we
observed significant H3K4me3 loss at their TSS without signifi-
cant changes in H3K27ac or H3K27me3 (Figure 6C). Of note,
genes with H3K4me3 increase were also identified in our ChIP-
seq analysis (Figure S6C).
To extend these observations to human breast cancer cells,
we performed H3K4me3 ChIP-seq in control and CBX8 knock-
down MDA-MB-231-Luc cells (Figures 6D and S6D). Consistent
with our findings of CBX8-regulated genes in human cells,
NOTCH3 showed a significant decrease of H3K4me3 at its
TSS (Figure 6E). Such a decrease was not observed at the
NOTCH1, 2, and 4 loci (Figure 6E), confirming NOTCH3 as an
effector of CBX8 in MDA-MB-231-Luc cells. Together, our data
suggest that CBX8 regulates specific NOTCH receptor expres-
sion through regulation of H3K4me3 and indicate a non-canon-
ical role for CBX8 by promoting gene activation.
Cbx8 Acts in a Non-canonical Fashion in Breast Cancer
To dissect the molecular mechanism of Cbx8 function, we
generated epitope tagged Cbx8 stable MMTV-Myc and MDA-
MB-231-Luc cell lines. Cbx8 localizes primarily to the chromatin
fraction (Figures S7A and S7B) and interacts with PRC1 mem-
bers, including Ring1b and Bmi1, suggesting that Cbx8 can be
incorporated into canonical PRC1 complexes (Figures 7A and
S7C). By eliminating H3K27me3 via EZH1/2 inhibitor treatment
(Konze et al., 2013), we observed a modest reduction of chro-
matin-bound Cbx8 in both cell lines (Figures S7D and S7E).
These data suggest that Cbx8 has the potential to function
through canonical PRC1 in these cells.
To test whether Cbx8 acts to promote tumorigenesis in the
context of PRC1, we knocked down Ring1b in MMTV-Myc cells.
Loss of Ring1b did not compromise TS formation, clonogenicity,
or proliferation in MMTV-Myc cells (Figures S7F–S7H). This is
consistent with the fact that while Ring1b shRNAs were present
in our library, they were not depleted in our TS screen. Further-
more, Ring1b knockdown did not reduce Notch-network
gene expression (Figure S7I). This suggests that while Cbx8
can participate in PRC1 complexes, its role in promoting breast
cancer may be independent of canonical PRC1.
To further investigate Cbx8-containing complexes, we per-
formed size exclusion chromatography. By screening for endog-
enous Cbx8-containing complexes, we identified multiple Cbx8
sub-complexes in MMTV-Myc cells (Figure 7B). We observed
a canonical PRC1 complex, consisting of Cbx8, Bmi1, and
Ring1b, as well as an uncharacterized Cbx8 complex lacking
PRC1 members. Here, Cbx8 co-fractionated with Wdr5, a core
member of the MLL methyltransferase complexes, which meth-480 Cell Reports 16, 472–486, July 12, 2016ylates H3K4. In addition, we observed an interaction between
Cbx8 andWdr5 in both MMTV-Myc and MDA-MB-231-Luc cells
(Figure 7C). While the Cbx8-Wdr5 interaction is not as robust
as the canonical Cbx8-PRC1 interactions (Figure 7A), these re-
sults suggest that Cbx8 has gene-activating roles, as we have
observed for Notch-network genes.
Functionally, Wdr5 knockdown significantly impaired TS for-
mation, clonogenicity, and invasiveness, as well as the expres-
sion of specific Notch-network genes in both MMTV-Myc and
MDA-MB-231-Luc cells (Figures 7D–7G and S7J–S7N), sug-
gesting that loss of Wdr5 recapitulates the effects of Cbx8
depletion. Moreover, ectopic expression of Wdr5 enhances TS
formation and rescues TS deficiency in Cbx8 knockdown cells
(Figure 7H). Finally, by using organoid cultures, which have low
expression of Notch receptors and ligands (Figure S5A), Wdr5
overexpression resulted in increased levels of Notch-network
genes (Figure 7I). Together, these data suggest that Cbx8 and
Wdr5 act cooperatively to regulate normal mammary stem cells
and breast tumorigenesis through regulation of Notch-network
genes. Therefore, our studies implicate a non-PRC1-dependent
role for Cbx8 in regulating H3K4me3 in the context of breast
cancer.
DISCUSSION
A Role for Cbx8 in Breast Cancer
Through a chromatin-focused RNAi screen using TS, we have
unveiled a role for Cbx8 in promoting breast cancer; Cbx8 is
required for tumorigenesis and malignant phenotypes of breast
cancer cells. CBX8 is overexpressed in primary breast tumors,
and high CBX8 expression in patients correlates with poor
outcome.We found that Cbx8 exerts its function in breast cancer
through maintaining gene expression of Notch signaling compo-
nents. Together, our data point toward a pivotal role for Cbx8 in
promoting breast tumorigenesis.
Data from TCGA show that CBX8 is altered in a broad range of
cancer types. Among these, breast cancer has one of the highest
rates of CBX8 genomic alteration, predominately amplification
(Figure S3A). This suggests that mammary epithelial cells are
sensitive to CBX8 dysregulation. Given that breast tissue con-
tains various populations of stem and progenitor cells (Visvader
and Stingl, 2014) and that our data suggest Cbx8 maintains
tumorigenesis via a stem-like gene expression program, investi-
gating the role of Cbx8 in normal mammary development and
stem and progenitor cells might shed light on the role of Cbx8
in breast tumor initiation.
Cbx8 Acts in a Non-canonical Manner in Breast Cancer
Here, we find that Cbx8 function is not entirely repressive and
can activate transcription in a PRC1-independent fashion. First,
our ChIP-seq data demonstrate (1) that Cbx8 is required for
maintaining H3K4me3, a histone modification found at the TSS
of active genes (Bernstein et al., 2005; Gaspar-Maia et al.,
2011), and (2) a positive correlation between H3K4me3 levels
andmRNA expression of Notch-network genes. Second, knock-
down of an integral PRC1 member, Ring1b, failed to phenocopy
Cbx8 loss of function in breast cancer cells. Finally, we identified
a non-PRC1 complex containing Cbx8 that co-fractionates with
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Figure 6. Cbx8 Maintains H3K4me3 at Notch-Network Gene Loci
(A) Average enrichment signal of H3K4me3, H3K27ac, and H3K27me3 at all annotated TSS (5 kb to +5 kb) in control and Cbx8 knockdown MMTV-Myc cells.
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decrease) upon Cbx8 knockdown in MMTV-Myc cells. Overlapping genes indicated.
(C) Overlay of H3K27me3, H3K27ac, and H3K4me3 (fold enrichment over input) at Notch1, Jag2, and Dll4 loci in control (orange) and Cbx8 knockdown (blue)
MMTV-Myc cells. Significantly decreased regions (FDR = 1 3 108) are underscored (blue bars).
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(E) Overlay of H3K4me3 atNOTCH1,NOTCH2,NOTCH3, andNOTCH4 in control andCBX8 knockdownMDA-MB-231-Luc cells. Significantly decreased regions
(FDR = 2 3 103) are underscored (green bars).
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Figure 7. Cbx8 Interacts with Wdr5 in Breast Cancer Cells
(A) Co-immunoprecipitation of Flag-Cbx8 with endogenous PRC1 members in MMTV-Myc cells.
(B) Size exclusion chromatography followed by immunoblotting of Cbx8-associated complexes in MMTV-Myc cells. Cbx8-containing PRC1 and non-PRC1
complexes are indicated by red and blue boxes, respectively.
(C) Co-immunoprecipitation of Flag-Cbx8 with Wdr5 in MMTV-Myc and MDA-MB-231-Luc cells.
(D) Real-time qPCR of control and Wdr5 knockdown MMTV-Myc cells. Rpl7 was used for normalization. Mean ± SEM (n = 3). *p < 0.05 compared to shScr.
(E) Immunoblotting of control and Wdr5 knockdown MMTV-Myc whole-cell lysate. Amido black staining of histones is used as loading control; numbers indicate
relative intensity of bands normalized to amido black.
(legend continued on next page)
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Wdr5 and further validated Wdr5 as a Cbx8 interacting protein.
These interactions may account for the non-canonical functions
of Cbx8 in breast cancer. However, we cannot exclude a role for
canonical PRC1 complex in tumorigenesis.
In agreement with our findings, recent evidence suggests that
Cbx8 is associated with gene activation in certain cellular con-
texts. In human fibroblasts, 38% of CBX8 binding regions
contain H3K4me3, and 28% of CBX8 targets are actively tran-
scribed (Pemberton et al., 2014). In ESCs, Cbx8 is transiently
bound to lineage genes for activation during early ESC differen-
tiation (Creppe et al., 2014). In addition, CBX8 can induce leuke-
mogenesis by cooperating with MLL-AF9 fusion protein and
Tip60 to activate HOX gene transcription. This function of
CBX8 is likely PRC1 independent, as RING1B and BMI1 knock-
down did not recapitulate the effect of CBX8 loss (Tan et al.,
2011). Together, these data suggest that CBX8 can activate
gene expression in either a PRC1-dependent or -independent
fashion. Collectively, we propose that CBX8’s role in activating
gene expression could be transient in normal cells, but become
deregulated and stable in tumor cells.
A Role for Cbx8 in Tumor-Initiating Cells?
Breast cancer contains a population of stem-like cells with
higher tumorigenic potential called breast-tumor-initiating
cells (BTIC) (Al-Hajj et al., 2003). The presence of such cells
is associated with drug resistance and poor patient survival
(Creighton et al., 2009; Pece et al., 2010). Consistent with pre-
vious studies (Dontu et al., 2003; Kurpios et al., 2013), we
show that TS culture functionally enriches for cells with BTIC
properties. Here, we uncover that Cbx8 is required for TS for-
mation, as well as other BTIC properties such as the ability to
initiate colonies at low cell confluency and to form tumors
in vivo at low cell numbers. Furthermore, we show that Cbx8
regulates Notch signaling, a pathway required to maintain
BTIC populations (Yamamoto et al., 2013). Our data also sug-
gest that Cbx8 regulates other known BTIC pathways, such as
Wnt signaling (Jang et al., 2015). Together, these data impli-
cate a potential role for Cbx8 in mediating BTIC populations
through Notch signaling and other oncogenic pathways for
future exploration.
Epigenetic Regulation of Notch in Breast Cancer
It is established that aberrant Notch signaling confers breast
carcinogenesis, therapy resistance, and the maintenance of
BTIC populations (Reedijk, 2012). In fact, transgenic overex-
pression of all four Notch receptors in the mouse mammary
gland leads to tumor formation (Gallahan and Callahan, 1997;
Hu et al., 2006a; Politi et al., 2004). Therefore, Notch inhibition
may serve as a novel therapeutic option for breast tumors.
However, inhibition of Notch signaling in the clinical setting
has been largely unsuccessful due to high toxicity and low(F) TS formation of control and Wdr5 knockdown MMTV-Myc cells. Mean ± SEM
(G) Clonogenic ability of control and Wdr5 knockdown MMTV-Myc cells. Mean ±
(H) Immunoblots (top) and TS formation (bottom) upon ectopic Myc-tagged Wdr5
H3 used as loading control. **p < 0.01, ***p < 0.0001.
(I) Real-time qPCR of Notch-network genes in control and Wdr5 overexpressed
(n = 3). *p < 0.05 compared to control.specificity of GSIs, which inhibit Notch receptor maturation.
In addition, despite the wealth of knowledge regarding Notch
signaling and Notch target genes, little is known about the up-
stream regulation of Notch receptors and ligands. Our study
has revealed a novel mechanism of Notch epigenetic regulation
in breast cancer. In light of the recent development of com-
pounds that inhibit Cbx function (Ren et al., 2015; Simhadri
et al., 2014; Stuckey et al., 2016), our studies provide support
for targeting Cbx8 as an alternative strategy to attenuate Notch
signaling in breast cancer. Specificity of inhibitory compounds
for Cbx orthologs will be essential for such therapeutic
targeting.EXPERIMENTAL PROCEDURES
Cell Culture
MMTV-Myc cells were derived from spontaneousmammary tumors of MMTV-
Myc transgenic mice and cultured in DMEM/F12 (Cellgro) with 2% fetal bovine
serum (FBS), 10 mg/ml insulin, 13 glutamine, 10 mM HEPES, 13 nonessential
amino acids, and 13 penicillin/streptomycin. MCF7, T47D, MDA-MB-157, and
MDA-MB-231-Luc cells were cultured in DMEM with 10% FBS and 13 peni-
cillin/streptomycin. MCF10A cells were cultured as described (Debnath et al.,
2003). TS were cultured in DMEM/F12 (Cellgro) or mammary epithelial basal
medium (MEBM, Lonza)with 20ng/ml EGF, 20 ng/ml bFGF, 13Gem21supple-
ment (Gemini Bio-products), and 13 penicillin/streptomycin on ultra-low
attachment plates (Corning) at a density < 1 3 106 cells per 10 ml media. TS
were dissociated with trypsin into single cells and passaged every 4 days.
TS RNAi Screen
The chromatin shRNA library targeting 60 genes (total of 452 shRNAs) was
cloned into pLKO.1 lentiviral vector with its puromycin resistance gene re-
placed with GFP in order to monitor transduction efficiencies. shRNA se-
quences were designed using The RNAi Consortium (TRC) algorithm. The
library was produced and sequenced to ensure proper coverage of shRNAs.
For screening, 100,000 MMTV-Myc cells were injected into the mammary fat
pad of two female FvB/N mice (10–16 weeks old). Tumors were harvested
two weeks later, dissociated into single cells and cultured as TS (1 3 106
cells per 10 ml media) or as bulk (adherent) cells for 3 days. TS were then
dissociated into single cells and 5 3 106 cells were transduced with the
shRNA library at a low MOI (<1) to ensure a single shRNA vector per cell. Af-
ter transduction, the cells were kept in suspension with rotation for 4 hr at
37C and subsequently replated as TS. 2 days later, a fraction of cells
from both conditions were analyzed by flow cytometry, and < 30% of cells
were GFP-positive, corresponding to single vector copy. TS cells were
passaged as above every 4 days to prevent aggregation and ensure selec-
tion. Bulk cells were passaged every 2 days. For both conditions, two cell
cultures from each tumor were passaged independently to serve as technical
replicates (total = four replicates). Cells from both conditions were collected
at day 0, 12, and 20 and genomic DNA was extracted. The integrated
shRNAs were amplified by PCR with primers containing multiplexing barco-
des and adaptors and sequenced on the Illumina HiSeq 2000 (ISMMS
Genomic Core Facility). Analyses and plots of the sequencing data were con-
ducted in Microsoft Excel and R statistical environment (R Foundation for
Statistical Computing, http://www.R-project.org). The hits were selected
based on the change of shRNA reads at day 12 and/or 20 versus day 0.
p values were calculated by comparing shRNA read numbers of the four(n = 10).
SEM (n = 4).
expression in control and Cbx8 knockdown MMTV-Myc cells (n = 10). Histone
mouse mammary organoids. Rpl7 was used for normalization. Mean ± SEM
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replicates (t test). Hit selection criteria are depicted in Figure S1E, and top 10
candidates are listed in Figure S1F.
TS Assays
Cells were trypsinized into single cells and cultured in ultra-low attachment
96-well plates in DMEM/F12 with 1.2% methylcellulose (to prevent cell aggre-
gation), with supplements as described above. Cells were seeded at low den-
sity (1,000–2,500 cell/ml) to ensure TS are derived from a single cell. After
8–12 days, TS larger than 200 mm were counted manually.
Native ChIP-Seq
Native ChIP-seq for H3K27me3 (Millipore, 07-449), H3K27ac (Abcam,
ab4729), and H3K4me3 (Abcam, ab1012) were performed in control
(shScramble) and Cbx8 knockdown cells (Cbx8-sh68 for MMTV-Myc cells;
CBX8-sh94 for MDA-MB-231-Luc cells) as described (Gaspar-Maia et al.,
2013). Input DNA was used to control for background. High-throughput
sequencing on all samples was performed using Illumina HiSeq 2500 with
100 nt single-end sequencing.
In vivo Tumorigenesis
Mouse studies performed under ISMMS IACUC number LA09-00382. See the
Supplemental Experimental Procedures for details.
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The accession number for the RNA-seq and ChIP-seq data reported in this
paper is GEO: GSE71077.
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